Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS pandemic, but none has yet succeeded. The lessons learned have repeatedly informed us that the traditional or conventional approaches directly using the pathogens or subunits will not be sufficient for an effective HIV/AIDS vaccine. Recent advances in structure-based technology have shown some promise in the quest for a better immunogen in HIV vaccine development. According to the basic binding structural relationship of an antigen and an antibody, structure-based antigen design could bring some hope for the development of an effective vaccine against HIV
HIV/AIDS remains one of the most important current threats to global public health. Since its identi...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
One of the promising approaches for designing HIV vaccines is construction of synthetic polyepitope ...
Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS pa...
Although vaccines have proven pivotal against arrays of infectious viral diseases, there are still n...
Although vaccines have proven pivotal against arrays of infectious viral diseases, there are still n...
Introduction: The development of a human immunodeficiency virus 1 (HIV-1) vaccine remains a formidab...
Despite over 30 years of effort, an HIV-1 vaccine that elicits protective antibodies still does not ...
The HIV-1 pandemic remains a major public health concern worldwide with over 1.5 million new infecti...
Vaccines provide the most cost effective defense against pathogens. Although vaccines have been desi...
Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope for...
AbstractHuman immunodeficiency virus (HIV) is the cause of one of the most lethal pandemics in human...
Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies, n...
The extraordinary genetic diversity and immune evasion of human immunodeficiency virus (HIV) pose si...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
HIV/AIDS remains one of the most important current threats to global public health. Since its identi...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
One of the promising approaches for designing HIV vaccines is construction of synthetic polyepitope ...
Many efforts have been made in the worldwide quest for a prophylactic HIV vaccine to end the AIDS pa...
Although vaccines have proven pivotal against arrays of infectious viral diseases, there are still n...
Although vaccines have proven pivotal against arrays of infectious viral diseases, there are still n...
Introduction: The development of a human immunodeficiency virus 1 (HIV-1) vaccine remains a formidab...
Despite over 30 years of effort, an HIV-1 vaccine that elicits protective antibodies still does not ...
The HIV-1 pandemic remains a major public health concern worldwide with over 1.5 million new infecti...
Vaccines provide the most cost effective defense against pathogens. Although vaccines have been desi...
Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope for...
AbstractHuman immunodeficiency virus (HIV) is the cause of one of the most lethal pandemics in human...
Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies, n...
The extraordinary genetic diversity and immune evasion of human immunodeficiency virus (HIV) pose si...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
HIV/AIDS remains one of the most important current threats to global public health. Since its identi...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
One of the promising approaches for designing HIV vaccines is construction of synthetic polyepitope ...